News

Stimulating Interactions

NEWS

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies Kite to License Cell Design Labs’ Synthetic Biology Technology for Applications in Acute Myeloid Leukemia with Exclusive Option for Applications in B-cell Malignancies Cell Design Labs’ Reversible ‘On/Off Switch’ Technology Provides Dynamic Range of Control to Precisely Regulate Activity of Engineered CAR […]

Read more

Cell Design Labs Executes Series of Private Financings

Cell Design Labs Executes Series of Private Financings New Company Focused on Discovering and Developing Next-Generation Immunotherapies for Cancer and Other Complex Diseases   SAN FRANCISCO, Calif. June 2, 2016 — Cell Design Labs, Inc. today announced it has executed a staged series of investor and strategic partner financings totaling $34.4 million to fund the company’s start-up operations. The investors, […]

Read more

Avant Completes Acquisitions of Amarantus, Theranostics Health

Avant Completes Acquisitions of Amarantus and Theranostics Health Avant Diagnostics announced today that it has completed its previously announced acquisitions of Amarantus Diagnostics and protein analysis services provider Theranostics Health. In January, Scottsdale, Arizona-based Avant inked a deal to merge with Amarantus Diagnostics, a subsidiary of therapeutics developer Amarantus Bioscience. The arrangement joins Amarantus’ research-use-only assays for multiple sclerosis and […]

Read more

ViewPoint Therapeutics Raises $4 Million in Series A Financing

ViewPoint Therapeutics Raises $4 Million in Series A Financing ViewPoint Therapeutics, Inc., a privately-held biotechnology company pioneering the development of crystallin stabilizers to prevent and treat cataracts and presbyopia, today announced the closing of a $4 million Series A financing. The transaction was co-led by Mission Bay Capital and Lagunita BioSciences LLC. Also included in the syndicate was healthcare-dedicated investor, […]

Read more

Miroculus Acquires Microfluidics Firm Kapplex

MicroRNA Diagnostics Developer Miroculus Acquires Microfluidics Firm Kapplex Miroculus, a San Francisco startup developing microRNA-based diagnostic tests, said Monday that it has acquired Toronto-based microfluidics firm Kapplex for an undisclosed amount. Miroculus emerged from stealth mode earlier this year at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference. It aims to tap into the growing evidence that miRNAs can serve as useful […]

Read more

Dow AgroSciences and TeselaGen to collaborate

A new collaboration between Dow AgroSciences and TeselaGen Biotechnology Inc. is designed to produce a biological design automation platform that can speed up discovery work for new agricultural products. “TeselaGen has created a powerful suite of tools for DNA design,” said Daniel R. Kittle, Ph.D., vice president, research and development, Dow AgroSciences. “These tools have the potential to accelerate our […]

Read more

Perlstein Lab continues their rare disease drug discovery

Perlstein Lab, or PLab as it is also known, continues to hone its automated drug discovery platform and presents its latest iteration Wednesday March 23rd at Y Combinator Demo Day. The platform they created helps the bio startup focus on finding cures for rare diseases rather than common ones. This novel approach is different from most Big Pharma labs and […]

Read more

Startup Miroculus Shares Vision for Rapid, Inexpensive miRNA Diagnostics at Tri-Con

Molecular diagnostics startup Miroculus is going all in on microRNAs as the ideal blood-based biomarker for diagnosing and monitoring a number of diseases and even tracking an individual’s general physiological well-being at the point of care and in resource-poor areas of the world, the company’s chief technology officer said this week. In a keynote presentation at Cambridge Healthtech Institute’s Molecular […]

Read more

IBM Watson adds Tiatros patient-centered social network to system

San Francisco start-up Tiatros, a doctor-driven, patient-centered social network, has joined the IBM Watson Ecosystem, the companies announced March 2 at HIMSS16. Tiatros was designed to allow physicians, with the consent of patients, to create a social network around the patient, including all doctors involved in their treatment and their family members. The first user of the platform was the […]

Read more

Immucor and Sirona Genomics receive the CE mark for Mia Fora NGS system for HLA typing

Immucor and Sirona Genomics announced this week that they have received the CE mark for their Mia Fora NGS system for HLA typing. The system is a high-resolution HLA typing solution for accurate coverage and analysis of 11 HLA genes. It is adapted for use on the Illumina MiSeq. The companies expect to launch a higher volume testing kit for […]

Read more
Page 3 of 812345...Last »

Upcoming Event

  • An Afternoon Tea Party for the Awesome 3 from the Magnificent 7!

    14:00-15:30
    08/31/2017
    1st Floor Conference Room, GEHC
    953 Indiana Street, San Francisco, CA 94107, United States
    RSVP From common-but-stubborn ailments like acne to the future of gene therapy or personalized cancer care, the breadth of biotech innovation happening in the Bay Area is vast. All told, the California Life Sciences Association estimates that the sector accounts for some 68,300 jobs in the region and nearly $1 billion in annual venture capital investment. To capture a snapshot of the work under way, the Business Times selected seven young scientists and entrepreneurs spanning established drugmakers, startups and academia. Though their interests and backgrounds are varied, they all have one thing in common: each is poised to make a major impact on the future of life sciences. Read the complete article at BizJournals

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter